Also, Bellanti et al. [40] investigated the effects of SGLT2 inhibitors on markers of oxidative stress, inflammation, liver steatosis, and fibrosis in 52 patients of T2D with NAFLD. Here, SLC5A2 is linked to Hepatic steatosis.